Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Thiomersal free trivalent influenza split vaccine 2003/2004 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects aged between 6 months and 3 years. |
| Group B | EXPERIMENTAL | Subjects aged 3 to 6 years. |
| Group C | ACTIVE_COMPARATOR | Subjects aged between 6 months and 3 years. |
| Group D | ACTIVE_COMPARATOR | Subjects aged 3 to 6 years. |
| Name | Type | Description |
|---|---|---|
| Thiomersal free trivalent influenza split vaccine 2003/2004 | BIOLOGICAL | 2 doses, intramuscular injection |
| GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004 | BIOLOGICAL | 2 doses, intramuscular injection |
Inclusion Criteria: * Subjects whose parents/guardians the investigator believes can and will comply with the requirements of the protocol * Male or female children over 6 months of age at the time of vaccination, but who are not yet 6 years old. * All children included in the study must never have...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
Thiomersal free trivalent influenza split vaccine 2003/2004 is an investigational influenza vaccine developed by GSK plc. It is a split-virus vaccine formulated without thiomersal, a mercury-based preservative. The product was designed for the 2003/2004 northern hemisphere influenza season and studied in a Phase 3 clinical trial in Germany.
It is used for the prevention of influenza. The vaccine targets seasonal influenza and was evaluated in healthy volunteers, including children from 6 months of age, in a Phase 3 study conducted in Germany. It is a trivalent split vaccine, meaning it contains three influenza virus strains.
GSK plc, which trades under the ticker GSK, is the developer of Thiomersal free trivalent influenza split vaccine 2003/2004. The vaccine was studied in a Phase 3 trial in Germany comparing it with standard thiomersal-containing formulations, Influsplit SSW and Fluarix, for the 2003/2004 season.
Thiomersal free trivalent influenza split vaccine 2003/2004 is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The study was randomized, double blind, and active controlled, enrolling 157 participants.
Thiomersal free trivalent influenza split vaccine 2003/2004 was studied in one completed Phase 3 trial, NCT00731393. The trial assessed immunogenicity and reactogenicity of the thiomersal-free trivalent influenza split vaccine 2003/04 compared with standard formulations Influsplit SSW and Fluarix 2003/04. It enrolled 157 healthy volunteers in Germany, including participants from 6 months of age.